We are live on ! Find out more

MaxCyte

MXCT

Market cap $120M

1.16 USD

-0.03

2.52%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

1.17

+0.01

0.86%

1 day

-2.52%

5 days

-7.2%

1 month

-6.45%

3 months

5.45%

6 months

43.65%

Year to date

-25.16%

1 year

-21.62%

5 years

-92.42%

10 years

-93.18%

About: MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Employees: 91

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 88.9%

Negative 0%

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte's common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte's common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte's SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte Q2 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.

MaxCyte Q2 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte Reports Second Quarter 2026 Financial Results

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company's $10 million share repurchase program authorized by the Board Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder's proprietary MiniVec™ plasmid system and MaxCyte's world-class clinical.

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™